BPC-157 + TB-500

It is a single lyophilised vial co-formulated with 5mg of BPC-157 and 5mg of TB-500, 10mg of total peptide, supplied under one batch number with one certificate of analysis reporting each component separately. BPC-157 is a 15-residue pentadecapeptide at 1419.53 g/mol and TB-500 is the 43-residue thymosin beta 4 sequence at 4963.4 g/mol. The blend exists to reduce preparation steps in combined-protocol research.

It is 1:1 by mass but not by moles, and the distinction matters for any molar calculation. BPC-157 has a molecular weight of 1419.53 g/mol and TB-500 of 4963.4 g/mol, so 5mg of each corresponds to roughly 3.5 µmol against roughly 1.0 µmol, a molar ratio near 3.5 to 1 in favour of BPC-157. A vial described as an equal-mass blend is therefore substantially BPC-157-weighted in molar terms.

Almost entirely for procedural reasons. A co-formulated vial requires one reconstitution rather than two, uses one fill volume and one solution, and removes a transfer step along with the sterility and volumetric error that step introduces. Both components also share a single reconstitution date and in-use window, which simplifies record-keeping. The pairing itself is common in preclinical tissue-repair designs because the two reported mechanisms are distinct rather than overlapping.

No controlled study has evaluated this specific combination, and that should be stated plainly rather than implied otherwise. Each compound has an extensive independent preclinical literature, BPC-157 centred on VEGFR2 signalling and focal adhesion kinase phosphorylation, thymosin beta 4 on G-actin sequestration and integrin-linked kinase activation. What does not exist is data demonstrating that the two together produce an effect beyond either alone. Any expectation of combination synergy is an assumption, not a published finding.

Per component, not as a single number. A meaningful certificate of analysis for a co-formulated vial has to resolve two chemically distinct species, a 1419 Da peptide and a 4963 Da peptide. Batch UKPL-2237 is verified by Janoshik Analytical (report #229864, Sep 2026) with a per-component content assay: 6.10mg BPC-157 and 5.64mg TB-500 measured in the vial. The report quantifies each component independently rather than quoting one aggregate figure, which is what makes it meaningful for a blend.

UK Peptide Lab supplies a pre-blended BPC-157 and TB-500 vial in the UK, 5mg plus 5mg, batch UKPL-2237, content-verified by Janoshik Analytical at 6.10mg BPC-157 and 5.64mg TB-500, with the certificate of analysis published on this page and same-day dispatch on orders placed before 3pm UK time. Free UK Royal Mail Tracked shipping over £69. Individual 5mg vials of each compound are also stocked for protocols needing them separately. Research use only, purchasers must be 18 or over.

Yes. The certificate for batch UKPL-2237 is published on this product page, and the batch record can be independently checked at /verify, which carries the Janoshik Analytical report #229864 (Sep 2026) on a per-batch verification page. UK delivery is free on orders over £69, dispatched the same day on orders placed before 3pm UK time on a working day.

No. It is equal by mass and about 3.5 to 1 by moles in favour of BPC-157. At 1419.53 g/mol and 4963.4 g/mol, 5mg of each is about 3.5 µmol against 1.0 µmol. Any protocol written in molar terms must allow for that.

No controlled study has tested this combination. Each peptide has its own preclinical literature, and they are often paired in tissue-repair designs because their reported mechanisms differ. No published work shows the pair does more than either alone. The blend is a format for convenience, not evidence of a combined effect.